Detection of autoantibodies against hypocretin, hcrtr1, and hcrtr2 in narcolepsy: Anti-hcrt system antibody in narcolepsy
Detection of autoantibodies against hypocretin, hcrtr1, and hcrtr2 in narcolepsy: Anti-hcrt system antibody in narcolepsy
复制标题
DOI:
10.1093/sleep/29.5.633
复制
发表时间:
2006-05-01
期刊:
影响因子:
5.6
通讯作者:
Honda, Makoto
中科院分区:
文献类型:
--
作者:
Tanaka, Susumu;Honda, Yutaka;Honda, Makoto
Study Objectives: The impairment of hypocretin neurotransmission system is considered to play a major role in the pathophysiology of narcolepsy. It has been hypothesized that autoimmune abnormalities underlie the etiology of narcolepsy, based on the tight association with HLA-DR131*1501/DQ1311*0602. It remains unclear if autoantibodies against hypocretin receptors (hcrtr1 and hcrtr2) are involved in narcolepsy.Design: We have developed a novel radioligand binding assay to address this question. Sera from 181 patients with narcolepsy, 10 patients with other hypersomnias, and 91 control subjects were used. Human [S-35]-Hcrt, hcrtr1, and hcrtr2 were synthesized by in vitro transcription/translation system. The immune complex of autoantibody and each [S-35]-protein were immunoprecipitated and quantified using a radioligand-binding assay.Results: We detected autoantibodies against hypocretin in 3 patients, hcrtr1 in 1 patient, and hcrtr2 in 5 patients with narcolepsy. Positive reactions were also found against hcrtr1 in 2 and hcrtr2 in I control subjects. No relationships were found between these autoantibodies and HLADRB1*1501/DQB1*0602 haplotypes, presence of cataplexy, presence of subjective nocturnal sleep disruption, or the score on the Epworth Sleepiness Scale.Conclusions: Although we have detected autoantibodies against the hypocretin neurotransmission system, our results do not support the hypothesis that autoantibody-mediated dysfunction in the hypocretin system underlies the pathophysiology of narcolepsy.